New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:22 EDTDG, ACHN, AZN, NSR, ADI, FDO, IDIX, CGIX, TSN, HITT, MRK, ODP, ALNY, HSHOn The Fly: Pre-market Movers
HIGHER: Idenix (IDIX), up more than 230% after Merck (MRK) acquires the company for $24.50 per share in cash of $3.85B. Idenix peer Achillion (ACHN) is up 35% after Merck's purchase... Hittite Microwave (HITT), up 29% after Analog Devices (ADI) agrees to acquire the company for $78 per share in cash... Family Dollar (FDO), up 11.6% following upgrade at Jefferies after Carl Icahn reported a 9.4% stake in the company. Dollar General (DG), which is being seen as potentially urged as a merger target for Family Dollar based on Icahn's stake, is up 8.6% after the news... Hillshire Brands (HSH), up 4.7% after Tyson Foods (TSN) submits unilaterally binding offer to acquire the company for $8.55B... Office Depot (ODP), up 4.6% after Barron's says shares could jump over 50%... Cancer Genetics (CGIX), up 6.4% after announcing partnership with AstraZeneca (AZN). LOWER: NeuStar (NSR), down 6.3% after calling FCC posting of confidential email "troubling"... Alnylam (ALNY), down 5.8% after presenting ALN-CC5 new pre-clinical data.
News For IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 25, 2015
08:08 EDTMRKMerck to present new data from IMPROVE-IT, TRA 2P studies
Subscribe for More Information
February 24, 2015
10:34 EDTACHNAchillion March calls active on renewed takeover chatter
Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:22 EDTACHNRumor: Achillion moves positive on renewed takeover chatter
Subscribe for More Information
07:47 EDTCGIXCancer Genetics to present new data at 2015 ASCO genitourinary cancers symposium
Subscribe for More Information
06:55 EDTODPOffice Depot sees $400M of cash merger integration expenses from 2014-2016
Subscribe for More Information
06:54 EDTODPOffice Depot expects to achieve synergy benefits of more than $750M by 2016-end
Subscribe for More Information
06:53 EDTODPOffice Depot sees FY15 sales to be lower than FY14, consensus $15.5B
Subscribe for More Information
06:52 EDTODPOffice Depot says acquisition by Staples to close by end of 2015
06:52 EDTODPOffice Depot reports Q4 N. American retail division sales $1.54B
Subscribe for More Information
06:51 EDTODPOffice Depot says 2015 operating priorities focus on synergies, efficiencies
Subscribe for More Information
06:51 EDTODPOffice Depot reports Q4 adjusted EPS 7c, consensus 4c
Reports Q4 revenue $3.83B, consensus $3.91B
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:57 EDTDGDollar General resumed with an Overweight at JPMorgan
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
07:22 EDTALNYSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGMs most recent financing. Merck will commit up to $250M to fund all of NGMs efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
07:23 EDTAZNAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZN, MRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use